Scarica l'app Stockscreener
7.56
2.58%
0.19
Dopo l'orario di chiusura:
7.56
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AURA Giù?
Forum
Previsione
Aura Biosciences Inc Borsa (AURA) Ultime notizie
Aura CEO to speak at Morgan Stanley healthcare event Sept. 16 - Stock Titan
Aura Biosciences (AURA) boosts finance chief with new stock grants - Stock Titan
COO at Aura Biosciences (AURA) lands new option and RSU package - Stock Titan
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aura Biosciences Grants Inducement Equity Awards to Newly Appointed Executives - Quiver Quantitative
Technical Reactions to AURA Trends in Macro Strategies - Stock Traders Daily
Aura Biosciences, Inc. SEC Filing (Aug 21, 2026) - Stock Titan
Long Focus Capital Management Expands Stake in Aura Biosciences Inc (AURA) With Strategic Add - GuruFocus
Aura (AURA) EPS and Revenue: The Bottom-Line Figure Trails Its Comparison for the Current Session; Price Move - vinanet.vn
Aura Biosciences Extends Bel-sar Data With Long-Term Follow-Up Study - TipRanks
AURA Q1 2026 Earnings: Wider Net Loss of $0.50 Per Share Weighs on SharesEstimate Revision Count - vinanet.vn
AURA Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Pre-Commercial Pipeline CostsRevenue Warning Signal - vinanet.vn
Wall Street Zen Downgrades Aura Biosciences (NASDAQ:AURA) to Sell - MarketBeat
Frazier funds disclose Aura Biosciences (AURA) stake and 9.99% warrant cap - Stock Titan
Aura Biosciences (AURA): Long Focus Capital reports 4.9% ownership - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP) - The Globe and Mail
HC Wainwright Raises Earnings Estimates for Aura Biosciences - MarketBeat
LifeSci Capital Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Aura Biosciences (AURA) files Form 3 for Chief People Officer Julie Person - Stock Titan
Aura Biosciences (AURA) officer Erica Kratz files initial Form 3 insider report - Stock Titan
Aura Biosciences (AURA) COO Susan Abu-Absi files initial insider Form 3 - Stock Titan
Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval - Seeking Alpha
AURA BIOSCIENCES, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $18 FROM $24 - webull.com
Aura refocuses clinical plans, reduces staff by 20% - The Business Journals
H.C. Wainwright Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Adage Capital discloses 9.1M Aura Biosciences (AURA) shares under shared control - Stock Titan
Aura Biosciences (NASDAQ:AURA) Shares Gap Down on Disappointing Earnings - marketbeat.com
H.C. Wainwright cuts Aura Biosciences stock price target on strategic shift - Investing.com Nigeria
Analysts Offer Predictions for AURA Q1 Earnings - marketbeat.com
Aura BiosciencesMay Offer Securities Up To $500 Million Aggregate - tradingview.com
Aura Biosciences (NASDAQ: AURA) sets $500M shelf and $200M ATM - stocktitan.net
Aura Biosciences Releases Q2 2026 Financial Results - AlphaStreet
HC Wainwright Lowers Aura Biosciences (NASDAQ:AURA) Price Target to $18.00 - MarketBeat
Aura Biosciences (NASDAQ:AURA) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPS - marketbeat.com
Aura Biosciences Extends Cash Runway Into First Half 202 - Minichart
Form 8K Aura Biosciences Inc For: 11 August By Investing.com - Investing.com Nigeria
Aura Biosciences (AURA) doubles assets after $280.8M raise as losses mount - stocktitan.net
Aura Biosciences Q2 Loss Widens - marketscreener.com
Aura Biosciences Restructures, Refocuses on Ocular Oncology - TipRanks
Earnings Flash (AURA) Aura Biosciences Posts Q2 Net Loss $0.48 a Share, vs. FactSet Est of $0.37 Loss - marketscreener.com
Aura Biosciences, Inc. Q2 2026: Net loss $45.6M, EPS $(0.48) — 10-Q Summary - TradingView
Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
AURA: Q2 net loss widened to $45.6M; $280.8M raised, restructuring shifts focus to ocular oncology - TradingView
Aura Biosciences Reports 45.6 Million Dollar Q2 Net Loss - Quiver Quantitative
AURA: Fully enrolled Phase 3 trial and strategic focus on ocular oncology extend cash runway to 1H 2029 - TradingView
Aura Biosciences, Inc. Announces Executive Changes - marketscreener.com
Aura Biosciences (AURA) Advances 4.42% to $8.04 as Oncology Pipeline Momentum BuildsProtective Put - dars.gov.et
Aura Biosciences (AURA) Drops 3.6% as Shares Test Critical $7.31 SupportTrend Continuation Trade - dars.gov.et
Responsive Playbooks and the AURA Inflection - Stock Traders Daily
Aura Biosciences (NASDAQ:AURA) Raised to Hold at Wall Street Zen - MarketBeat
Aura Biosciences Expands Authorized Shares and Incentive Plan - TipRanks
Aura Biosciences (AURA) Projected to Announce Quarterly Earnings on Wednesday - MarketBeat
AURA Q2'26 Earnings: EPS estimate is (0.38) USD - TradingView
InvestingPro Fair Value predicted Aura Biosciences’ 40% decline By Investing.com - Investing.com Nigeria
Aura Biosciences, Inc. Revenue Breakdown – NASDAQ:AURA - TradingView
AURA Q1 2026 Earnings: Wider-than-Expected Loss of -$0.50 per Share as Pipeline Investment ContinuesRevenue Breakdown Analysis - Vinanet
AURA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Understanding the Setup: (AURA) and Scalable Risk - Stock Traders Daily
Aura Biosciences Inc (AURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AURA|Aura Biosciences Inc|Price:7.155|Chg%:+0.105 - TradingKey
BlackRock (AURA holder) discloses 4.4% Aura Biosciences stake in amended filing - Stock Titan
Aura Biosciences Inc (AURA) Institutional Confidence - TradingKey
Aura Biosciences Inc (AURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):